Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2015-05-18 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science EN
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science detailing that three clinical abstracts related to their drug masitinib will be presented at the 2015 ASCO Annual Meeting. It provides details about the abstracts, study summaries, and references to previous press releases regarding preliminary data. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing announcing a transaction or management change. It is an announcement about participation in a scientific/industry conference, which falls under general investor/corporate communication. Since it is a specific announcement about company progress and data presentation, and not a general regulatory filing (RNS) or a presentation document (IP), the closest fit among the provided options for corporate updates that aren't strictly financial results or management changes is often a general Investor Relations communication. However, given the content is focused on clinical trial data presentation at a major medical conference, it is a form of Investor Presentation material or a general corporate update. Since it is an announcement *about* presentations rather than the presentation itself, and it is not a standard financial report, it is best classified as a general Regulatory Filing (RNS) as a catch-all for specific, non-standard corporate news, or potentially Investor Presentation (IP) if the content were the slides themselves. Given the structure (press release style announcement), RNS is the most appropriate fallback for specific, non-standard corporate news that doesn't fit the other categories.
2015-05-18 English
AB Science FR
Earnings Release Classification · 99% confidence The document is a press release dated May 18, 2015, announcing that AB Science will present results from three Phase 2 clinical studies (masitinib in metastatic colorectal cancer, stomach cancer, and triple-negative breast cancer) at the upcoming 2015 American Society of Clinical Oncology (ASCO) annual meeting. The text details the abstracts, presentation times, and provides commentary on the drug's potential. This is not a full regulatory report (like 10-K or IR), nor is it a transcript (CT) or a formal dividend/share change notice. It is an announcement about scientific data being presented at a major industry conference, which falls under general investor/scientific communication. Since the core purpose is announcing the presentation of clinical data at a scientific meeting, it aligns best with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the focus on presenting detailed study results (even if summarized) intended for investors and the scientific community, 'Investor Presentation' (IP) is a strong fit, as these announcements often precede or accompany investor briefings. However, since it is explicitly an announcement about abstracts being presented at a third-party conference, and not the presentation material itself, it is more accurately classified as a general announcement of scientific progress, which often defaults to RNS if IP is too specific to a company-created deck. Reviewing the definitions, 'IP' is for a detailed presentation by the company. This is an announcement *about* presentations by others (investigators) at an external conference. Therefore, 'RNS' (Regulatory Filings / General regulatory announcements) is the most appropriate fallback for this type of scientific progress update announcement that doesn't fit the other specific categories. FY 2015
2015-05-18 French
AB Science EN
Investor Presentation Classification · 95% confidence The document is a summary of a web conference held on May 11, 2015, regarding the ongoing Phase 3 study of Masitinib for ALS. It details the results of a futility test passed by the Independent Data Safety and Monitoring Committee (IDMC) and outlines the plan for the next interim analysis scheduled for Q1 2016. This content is a detailed update on clinical trial progress and future analysis plans, which is typical of an Investor Presentation (IP) or a detailed update provided to investors, rather than a formal regulatory filing like a 10-K or a brief Earnings Release (ER). Since it is a structured presentation summarizing scientific and trial progress for stakeholders, 'Investor Presentation' (IP) is the most appropriate classification.
2015-05-11 English
AB Science FR
Regulatory Filings Classification · 95% confidence The document is titled "Compte rendu de la conférence web sur le masitinib dans la sclérose latérale amyotrophique (SLA)" (Summary of the web conference on masitinib in amyotrophic lateral sclerosis (ALS)). It details the status of a Phase 3 clinical trial (AB10015), including the successful futility test passed by the Independent Data Monitoring Committee (IDMC) and outlines the next steps, specifically an interim analysis planned for Q1 2016. This content is a summary or report of a specific event (a web conference) discussing clinical trial progress and future plans, rather than a formal regulatory financial filing like a 10-K, an Earnings Release (ER), or a comprehensive Interim Report (IR). Since it is a summary/report of a specific event, and the content is highly focused on clinical development updates, it most closely aligns with an Investor Presentation (IP) or a general regulatory announcement. Given the context of providing detailed updates on clinical trials and future milestones to investors, 'Investor Presentation' (IP) is the most appropriate fit, although it is presented as a 'Compte rendu' (Summary/Transcript) of a web conference. However, since 'Call Transcript' (CT) is defined as the full text transcript of conference calls, and this is a summary/press release *about* the conference, IP is a better fit than CT. It is not a general regulatory filing (RNS) because it is too specific to investor/clinical updates.
2015-05-11 French
AB Science EN
Share Issue/Capital Change Classification · 95% confidence The document is titled 'INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL' (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly references Article 221-1 and 223-16 of the AMF General Regulation (French financial regulator). It provides a table showing the total number of shares and voting rights as of a specific date (April 30, 2015). This type of mandatory periodic disclosure regarding the capital structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning share capital and voting rights, which aligns best with the general 'Regulatory Filings' (RNS) category as a fallback, or potentially a specialized capital/financing update, but RNS is the most appropriate general regulatory disclosure bucket when a more specific one isn't available among the provided list for this exact content type (which is often reported monthly in France). Given the options, RNS serves as the best fit for a general, non-financial-result-focused regulatory update.
2015-05-07 French
AB Science EN
Regulatory Filings Classification · 95% confidence The document is a press release dated May 5, 2015, announcing that Chardan Capital Markets has initiated research coverage on AB Science with a BUY recommendation and a target price. This type of announcement, which relays external analyst opinions and research initiation, does not fit neatly into the defined categories like Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is an announcement related to investor relations and market coverage. Since it is not a formal regulatory filing (like a 10-K or DEF 14A) but rather a specific piece of market-related news, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory or market announcements that don't fit elsewhere, although 'Investor Presentation' (IP) or 'Management Reports' (MDA) are sometimes used for analyst coverage, RNS is the best fit for a general announcement about external research initiation.
2015-05-05 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.